Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study

[1]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[2]  P. Prandoni,et al.  The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience , 2020, Journal of Thrombosis and Haemostasis.

[3]  E. de Jonge,et al.  Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease? , 2020, Thrombosis Research.

[4]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[5]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[6]  P. Reitsma,et al.  Pulmonary embolism , 2018, Nature Reviews Disease Primers.

[7]  F. Klok,et al.  Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature , 2017, European Respiratory Journal.

[8]  T. van der Poll,et al.  New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology , 2004, Annals of medicine.

[9]  M. Levi,et al.  Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors , 2002, The Lancet.

[10]  A Vieillard-Baron,et al.  New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. , 2001, AJR. American journal of roentgenology.